AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...
AstraZeneca is a leader in cancer treatments with FDA-approved drugs. Read why AZN stock is still a 'Buy' and why the company’s future looks bright.
Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...
AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...
AstraZeneca PLC on Thursday announced a USD570 million investment in Canada, creating more than 700 jobs, across all areas of the business. The Cambridge-based pharmaceuticals company said the ...
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
AstraZeneca announced a new investment in Canada to support the company’s move into a larger, more modern facility in Greater ...
AstraZeneca, a global pharmaceutical company focused on developing life changing medicines, today announced a C$820 million (US$570m) investment in Canada, creating more than 700 high-skilled jobs, ...
AstraZeneca is expanding its boot print in Canada with a $570 million investment designed to create 700 jobs. | AstraZeneca is expanding its boot print in Canada with a $570 million investment ...
AstraZeneca plans C$820 million investment in Canada to advance growing global hub and clinical delivery: Mississauga, Ontario Saturday, January 25, 2025, 09:00 Hrs [IST] AstraZen ...